1stOncology™: Cancer Intelligence Service – Page 2495 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

General Proximity Has Been Selected as One of the 24 ARPA-H Sprint for Women’s Health Awardees to Receive $3M to Develop Our Main Program

On October 23, 2024 General Proximity reported the company has been selected as one of the 24 awardees of the highly competitive Advanced Research Projects Agency for Health (ARPA-H) Sprint for Women’s Health (Press release, General Proximity, OCT 23, 2024, View Source [SID1234649816]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Chosen from over 1,700 applicants representing 34 countries, this recognition underscores the transformative potential of our technology in addressing unmet needs in women’s health. This $3M award will support our team as we advance next-gen proximity therapeutics for high value undruggable targets in the women’s cancer space toward the clinic.

We are honored by ARPA-H’s support on this groundbreaking program and remain committed to advancing solutions that redefine possibilities in women’s healthcare.

Q3 2024 Highlights

On October 23, 2024 Boston Scientific Corporation (NYSE: BSX) reported net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period (Presentation, BTG, OCT 23, 2024, View Source [SID1234649614]).

Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months

On October 23, 2024 Hoffmann-La Roche reported strong sales growth of 9% (CER) continues in the third quarter of 2024 (Press release, Hoffmann-La Roche, OCT 23, 2024, View Source [SID1234649078]).

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

On October 23, 2024 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, reported its performance for the year to date and the third quarter of 2024 (Press release, Ipsen, OCT 23, 2024, View Source [SID1234648245]).

BostonGene to Participate in the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

On October 23, 2024 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported that it will participate in the 36th edition of the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), taking place October 23-25, 2024, at the International Barcelona Convention Center in Barcelona, Spain (Press release, , OCT 23, 2024, View Source [SID1234647358]). The event will bring together academics, scientists and industry leaders from around the world to discuss innovations in drug development, target selection and translational cancer research. ENA 2024 offers a valuable platform for in-depth scientific discussions on preclinical and phase I studies and for sharing insights on advancements in molecular targets and cancer therapeutics, with a focus on the implications of molecular biology discoveries.

Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene, will be a featured speaker during the symposium. Dr. Lennerz will participate in a workshop titled "Innovation and Biomarkers in Cancer Drug Development," where he will deliver a presentation, "FDA’s Oversight of Laboratory Developed Tests: Taming the Wild West in Daily Practice." The presentation is scheduled for October 23, from 16:15 to 16:40 PM, in Room 113+114. Dr. Lennerz will discuss the critical role of regulatory oversight in advancing laboratory-developed tests and their impact on clinical practice, addressing current challenges and exploring solutions to ensure accuracy, reliability and patient safety.

"BostonGene is excited to engage with the international community at ENA 2024," said Dr. Lennerz. "We are eager to share our insights on the regulatory landscape and the importance of biomarkers in shaping the future of cancer therapeutics. The presentation will underscore the need for robust regulatory frameworks to support innovation, speed up drug discovery and ultimately enhance patient outcomes in this rapidly evolving field."

Visit the ENA 2024 website for more information.